Prescribing peritoneal dialysis for high-quality care in children

2020 ◽  
Vol 40 (3) ◽  
pp. 333-340
Author(s):  
Bradley A Warady ◽  
Franz Schaefer ◽  
Arvind Bagga ◽  
Francisco Cano ◽  
Mignon McCulloch ◽  
...  

Background: Peritoneal dialysis (PD) remains the most widely used modality for chronic dialysis in children, particularly in younger children and in lower and middle income countries (LMICs). We present guidelines for dialysis initiation, modality selection, small solute clearance, and fluid removal in children on PD. A review of the literature and key studies that support these statements are presented. Methods: An extensive Medline search for all publications on PD in children was performed using predefined search criteria. Results: High-quality randomized trials in children are scarce and current clinical practice largely relies on data extrapolated from adult studies or drawn from observational cohort studies in children. The evidence and strength of the recommendation is GRADE-ed, but in the absence of high-quality evidence, the opinion of the authors is provided and must be carefully considered by the treating physician, and adapted to local expertise and individual patient needs as appropriate. We discuss the timing of dialysis initiation, factors to be considered when selecting a dialysis modality, the assessment and management of volume status on PD, achieving optimal small solute clearance, and the importance of preserving residual kidney function. While optimal dialysis must remain the goal for every patient, a careful discussion with fully informed patients and caregivers is important to understand the patient and family’s expectations of dialysis and reasonable adjustments to the dialysis program may be considered in accordance with a philosophy of shared decision-making. Conclusions: There continues to be very poor evidence in the field of chronic PD in children and these recommendations can at best serve to guide clinical decision-making. In LMICs, every effort should be made to conform to the framework of these statements, taking into account resource limitations.

2020 ◽  
Vol 40 (3) ◽  
pp. 254-260 ◽  
Author(s):  
Neil Boudville ◽  
Thyago Proença de Moraes

Background: The International Society for Peritoneal Dialysis guidelines for small solute clearance and fluid removal in peritoneal dialysis (PD) were published in 2005. The aim of this article is to update those guidelines by reviewing the literature that supported those guidelines and examining publications since then. Methods: An extensive search of publications was performed through electronic databases and a hand search through reference lists from the existing guideline and selected articles. Results: There have been no prospective intervention trials to inform the area of small solute clearance in PD since the publication of the original guideline in 2005. The trials to date are largely limited to a few prospective cohort studies and retrospective studies. These have, however, consistently demonstrated that residual renal function (RRF) is more often associated with patient outcome than peritoneal clearance. One of the few randomised controlled trials performed in this area does suggest that a weekly Kt/ V of 2.27 ± 0.02 provides no statistically significant survival advantage over a weekly Kt/ V of 1.80 ± 0.02. The lower limit of Kt/ V is unknown but there is weak evidence to suggest that anuric people doing PD should have a weekly Kt/ V of at least 1.7. Conclusions: There continues to be very poor evidence in the area of small solute clearance and fluid removal in PD. The evidence that exists suggests that RRF is more important than peritoneal clearance and that there appears to be no survival advantage in aiming for a weekly Kt/ V >1.70.


2019 ◽  
Vol 2 (3) ◽  
pp. 151-157
Author(s):  
Anna Lima ◽  
Joana Tavares ◽  
Nicole Pestana ◽  
Maria João Carvalho ◽  
António Cabrita ◽  
...  

In peritoneal dialysis (PD) (as well as in hemodialysis) small solute clearance measured as Kt/v urea has long been used as a surrogate of dialysis adequacy. A better urea clearance was initially thought to increase survival in dialysis patients (as shown in the CANUSA trial)(1), but  reanalysis of the data showed a superior contribution of residual renal function as a predictor of patient survival. Two randomized controlled trials (RCT)(2, 3)  supported this observation, demonstrating no survival benefit in patients with higher achieved Kt/v. Then guidelines were revised and a minimum Kt/v of 1,7/week was recommended but little emphasis was given to additional parameters of dialysis adequacy. As such, volume overload and sodium removal have gained major attention, since their optimization has been associated with decreased mortality in PD patients(4, 5). Inadequate sodium removal is associated with fluid overload which leads to ventricular hypertrophy and increased cardiovascular mortality(6). Individualized prescription is key for optimal sodium removal as there are differences between PD techniques (CAPD versus APD) and new strategies for sodium removal have emerged (low sodium solutions and adapted PD). In conclusion, future guidelines should address parameters associated with increased survival outcomes (sodium removal playing an important role) and abandon the current one fit all prescription model.


2003 ◽  
Vol 23 (2_suppl) ◽  
pp. 65-68 ◽  
Author(s):  
Philip K.T. Li ◽  
Cheuk-chun Szeto

Sufficient data are available to support the contention that renal and peritoneal clearances are not equivalent, and that loss of residual renal function (RRF) cannot be completely compensated by an increase in the exchange volume or frequency of peritoneal dialysis. When RRF is minimal (for example, renal Kt/V is 0.1 – 0.3), increasing the peritoneal Kt/V beyond the “conventional” value recommended by the Dialysis Outcomes Quality Initiative yields little additional clinical benefit. The cut-off peritoneal ( not total) Kt/V is possibly 1.6 – 1.7. However, delivery of peritoneal small-solute clearance below that cut-off level has a major detrimental effect on clinical outcome in CAPD patients with little RRF. Measures to preserve RRF therefore become an important goal in the treatment of CAPD patients. In short, with regard to RRF (renal Kt/V), higher is always better, and we should always try to preserve it. For peritoneal Kt/V, higher is better only up to a certain limit. The importance of aspects of adequate dialysis other than small-solute removal—especially fluid removal, blood pressure control, nutrition, acid–base balance, mineral metabolism, and anemia and lipid control—cannot be sufficiently emphasized.


Nephrology ◽  
2005 ◽  
Vol 10 (s4) ◽  
pp. S81-S85 ◽  
Author(s):  
DAVID JOHNSON ◽  
FIONA BROWN ◽  
HELEN LAMMI ◽  
ROBERT WALKER

2020 ◽  
Vol 29 (10) ◽  
pp. 1.3-2 ◽  
Author(s):  
Linda M Isbell ◽  
Julia Tager ◽  
Kendall Beals ◽  
Guanyu Liu

BackgroundEmergency department (ED) physicians and nurses frequently interact with emotionally evocative patients, which can impact clinical decision-making and behaviour. This study introduces well-established methods from social psychology to investigate ED providers’ reported emotional experiences and engagement in their own recent patient encounters, as well as perceived effects of emotion on patient care.MethodsNinety-four experienced ED providers (50 physicians and 44 nurses) vividly recalled and wrote about three recent patient encounters (qualitative data): one that elicited anger/frustration/irritation (angry encounter), one that elicited happiness/satisfaction/appreciation (positive encounter), and one with a patient with a mental health condition (mental health encounter). Providers rated their emotions and engagement in each encounter (quantitative data), and reported their perception of whether and how their emotions impacted their clinical decision-making and behaviour (qualitative data).ResultsProviders generated 282 encounter descriptions. Emotions reported in angry and mental health encounters were remarkably similar, highly negative, and associated with reports of low provider engagement compared with positive encounters. Providers reported their emotions influenced their clinical decision-making and behaviour most frequently in angry encounters, followed by mental health and then positive encounters. Emotions in angry and mental health encounters were associated with increased perceptions of patient safety risks; emotions in positive encounters were associated with perceptions of higher quality care.ConclusionsPositive and negative emotions can influence clinical decision-making and impact patient safety. Findings underscore the need for (1) education and training initiatives to promote awareness of emotional influences and to consider strategies for managing these influences, and (2) a comprehensive research agenda to facilitate discovery of evidence-based interventions to mitigate emotion-induced patient safety risks. The current work lays the foundation for testing novel interventions.


2015 ◽  
Vol 51 ◽  
pp. 378-397 ◽  
Author(s):  
Barbara Bowers ◽  
Tonya Roberts ◽  
Kimberly Nolet ◽  
Brenda Ryther ◽  

2009 ◽  
pp. 478-487
Author(s):  
Sharon J. Nessim ◽  
Joanne M. Bargman

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 6551-6551 ◽  
Author(s):  
Blair Billings Irwin ◽  
Yousuf Zafar ◽  
Ivy Altomare ◽  
Gretchen Genevieve Kimmick ◽  
P. Kelly Marcom ◽  
...  

6551 Background: The American Society of Clinical Oncology has suggested that patient-physician discussion of costs is a component of high quality care. Little data exists on patients’ experience confronting costs or attitudes on how cost should be addressed. Methods: We distributed a self-administered anonymous paper survey to consecutive patients with breast cancer presenting for a routine visit within 5 years of diagnosis at an academic center. Survey questions addressed financial distress, experience and preferences concerning discussions of cost, and views on cost control. Results are primarily descriptive, with comparison among patients on the basis of disease stage using Fisher’s exact test. All p-values are 2-sided. Results: We surveyed 134 patients (response rate 86%). Median age was 61. 72% stage I-III disease, and 28% (n=36) had stage IV disease. 44% (n=57) reported at least a moderate level of financial distress. Only 14% (n=18) reported ever discussing costs with their doctor, though 94% (n=121) felt doctors should talk to patients about costs. 53% (n=69) felt doctors should discuss direct costs with patients but only 38% (n=49) felt doctors should consider costs to society or insurance companies in their decision-making. Patients with metastatic disease were significantly less likely than those with earlier stage disease to want doctors to consider societal costs (33% (n=24) vs 6% (n=2), p<0.01). 88% (n=114) reported concern over costs of cancer care, but there was no consensus on how to control costs. Only 3% (n=4) favored greater cost sharing and 9% (n=11) supported greater means testing. A minority (33%, n=43) supported reducing drug costs through government price controls (33% n=43). The majority endorsed generic substitution (59%, n=75) and preferential selection of drugs which prolong survival 53% (n=69). Conclusions: Although many patients with breast cancer want to discuss costs of care with their doctors, there is little consensus on the ideal content of these discussions. Few patients support consideration of societal costs in clinical decision-making. Further research is needed to evaluate the potential for patient-physician discussions of cost to contribute to affordable high quality cancer care.


Sign in / Sign up

Export Citation Format

Share Document